Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia
- PMID: 37448768
- PMCID: PMC10336924
- DOI: 10.3892/mi.2023.94
Characteristics and outcomes of elderly patients with Parkinson's disease hospitalized due to COVID‑19‑associated pneumonia
Abstract
Patients with Parkinson's disease (PD) and coronavirus disease 2019 (COVID-19)-associated pneumonia present, according to the literature, high mortality rates due to the nature of the disease, advanced age, and underlying diseases. Most available studies, however, refer to the first waves of the pandemic. The aim of the present study was to investigate the clinical characteristics and outcomes of elderly patients (≥65 years old) with PD hospitalized with COVID-19-associated pneumonia during the period of prevalence of various severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, as well as to determine possible prognostic factors for poor outcomes. During the period from February 15, 2021, to July 15, 2022, 1,144 elderly patients with COVID-19 pneumonia were hospitalized. Age, sex, Charlson comorbidity index, vaccination status against SARS-CoV-2, and admission laboratory parameters were recorded for all patients. A total of 36 (3.1%) patients with PD were hospitalized due to COVID-19-associated pneumonia (18 males, 50%). The mean age of the patients was 82.72±8.18 years. In total, 8 patients (22.2%) were hospitalized during the period of alpha variant predominance, 3 patients (8.3%) during the period of delta variant predominance, and 25 patients (69.4%) during the omicron variant predominance period. Of note, 16 patients (44.4%) were vaccinated with at least two doses. In addition, 17 (47.2%) patients succumbed to the disease. Between the patients who survived and those who succumbed, a statistically significant difference was only found in the mean value of albumin (37.48±6.02 vs. 31.97±5.34 g/l, P=0.019). In particular, as shown by receiver operating characteristic curve analysis, albumin exhibited a satisfactory predictive ability for mortality (area under the curve, 0.780; P=0.013) with an albumin value ≤37.7 g/l being able to predict mortality with 85.7% sensitivity and 54.8% specificity. Overall, the findings of the present study indicate that mortality among elderly patients with PD hospitalized with COVID-19-associated pneumonia was high in all phases of the pandemic. A low albumin value, not only as an indicator of the immune status, but also of the nutritional status, is a predictor of adverse outcomes.
Keywords: Parkinson's disease; albumin; coronavirus disease 2019; mortality; pneumonia.
Copyright: © Georgakopoulou et al.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures
Similar articles
-
Predictors of COVID‑19‑associated mortality among hospitalized elderly patients with dementia.Exp Ther Med. 2023 Jul 3;26(2):395. doi: 10.3892/etm.2023.12094. eCollection 2023 Aug. Exp Ther Med. 2023. PMID: 37456163 Free PMC article.
-
Risk factors for the in‑hospital and 1‑year mortality of elderly patients hospitalized due to COVID‑19‑related pneumonia.Exp Ther Med. 2023 Nov 20;27(1):22. doi: 10.3892/etm.2023.12310. eCollection 2024 Jan. Exp Ther Med. 2023. PMID: 38125348 Free PMC article.
-
Clinical Characteristics and Outcomes Among Adults Hospitalized with Laboratory-Confirmed SARS-CoV-2 Infection During Periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) Variant Predominance - One Hospital, California, July 15-September 23, 2021, and December 21, 2021-January 27, 2022.MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223. doi: 10.15585/mmwr.mm7106e2. MMWR Morb Mortal Wkly Rep. 2022. PMID: 35143466 Free PMC article.
-
Onodera's prognostic nutritional index: Comparison of its role in the severity and outcomes of patients with COVID‑19 during the periods of alpha, delta and omicron variant predominance.Exp Ther Med. 2022 Sep 16;24(5):675. doi: 10.3892/etm.2022.11611. eCollection 2022 Nov. Exp Ther Med. 2022. PMID: 36177343 Free PMC article.
-
Parkinson's disease may worsen outcomes from coronavirus disease 2019 (COVID-19) pneumonia in hospitalized patients: A systematic review, meta-analysis, and meta-regression.Parkinsonism Relat Disord. 2021 Jun;87:155-161. doi: 10.1016/j.parkreldis.2021.04.019. Epub 2021 Apr 24. Parkinsonism Relat Disord. 2021. PMID: 33931304 Free PMC article.
Cited by
-
Neurological Examination via Telemedicine: An Updated Review Focusing on Movement Disorders.Medicina (Kaunas). 2024 Jun 9;60(6):958. doi: 10.3390/medicina60060958. Medicina (Kaunas). 2024. PMID: 38929575 Free PMC article. Review.
-
A mid‑pandemic night's dream: Melatonin, from harbinger of anti‑inflammation to mitochondrial savior in acute and long COVID‑19 (Review).Int J Mol Med. 2024 Mar;53(3):28. doi: 10.3892/ijmm.2024.5352. Epub 2024 Feb 1. Int J Mol Med. 2024. PMID: 38299237 Free PMC article. Review.
-
The parallel lives of pandemics: COVID‑19 and obesity.Exp Ther Med. 2024 Mar 6;27(5):184. doi: 10.3892/etm.2024.12472. eCollection 2024 May. Exp Ther Med. 2024. PMID: 38550351 Free PMC article.
-
SARS-CoV-2 and Parkinson's Disease: A Review of Where We Are Now.Biomedicines. 2023 Sep 13;11(9):2524. doi: 10.3390/biomedicines11092524. Biomedicines. 2023. PMID: 37760965 Free PMC article. Review.
-
Lung function at three months after hospitalization due to COVID‑19 pneumonia: Comparison of alpha, delta and omicron variant predominance periods.Exp Ther Med. 2024 Jan 5;27(2):83. doi: 10.3892/etm.2024.12372. eCollection 2024 Feb. Exp Ther Med. 2024. PMID: 38274344 Free PMC article.
References
-
- Frontera JA, Sabadia S, Lalchan R, Fang T, Flusty B, Millar-Vernetti P, Snyder T, Berger S, Yang D, Granger A, et al. A prospective study of neurologic disorders in hospitalized patients with COVID-19 in New York City. Neurology. 2021;96:e575–e586. doi: 10.1212/WNL.0000000000010979. - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous